Fast-growing semiconductor and next-generation biotech stocks can create lucrative new markets in healthcare and computing and beat the benchmark over the long term, says Martin Currie’s equities investment boss, Zehrid Osmani.
The fund manager said Martin Currie’s global fund also owns $US32.4 billion Nasdaq-listed genetic sequencing biotech Illumina. Grail also uses some of Illumina’s gene sequencing technology to deliver the result for its fast-selling blood tests.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
مصدر: FinancialReview - 🏆 2. / 90 اقرأ أكثر »